Valuation: Enimmune corporation

Market Cap 1.2B 37.14M 32.65M 30.4M 27.91M 52.42M 3.56B 53.11M 361M 141M 1.76B 139M 136M 6.08B P/E 2024
-11.3x
P/E 2025 -9.04x
Enterprise Value 1.15B 35.45M 31.17M 29.01M 26.65M 50.03M 3.4B 50.69M 345M 135M 1.68B 133M 130M 5.8B EV / Sales 2024
35.4x
EV / Sales 2025 29.7x
Free-Float
28.72%
Yield 2024 *
-
Yield 2025 -
1 week+2.78%
Current month+4.06%
1 month+7.77%
3 months-14.40%
6 months-17.16%
Current year-19.17%
1 week 16.15
Extreme 16.15
17.1
1 month 15.4
Extreme 15.4
17.1
Current year 15.4
Extreme 15.4
22.15
1 year 15.4
Extreme 15.4
23.9
3 years 14.65
Extreme 14.65
49.3
5 years 14.65
Extreme 14.65
75.3
10 years 14.49
Extreme 14.49
125
Manager TitleAgeSince
Chief Executive Officer - 07/01/2019
Chief Tech/Sci/R&D Officer - 21/07/2014
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman - 07/01/2019
Director/Board Member - 02/01/2014
Director/Board Member - 19/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.78%-1.48%-64.80% 37.13M
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-1.16%-1.27%+3.84%+417.94% 23.18B
+2.80%-0.38%-18.60%-12.56% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.28%+0.96%+26.30%+186.05% 13.92B
Average +0.64%+1.67%+37.85%+153.58% 24.01B
Weighted average by Cap. +0.06%+1.93%+39.93%+138.68%

Financials

2024 2025
Net sales 39.92M 1.23M 1.09M 1.01M 928K 1.74M 118M 1.76M 12.01M 4.69M 58.45M 4.63M 4.53M 202M 48.19M 1.49M 1.31M 1.22M 1.12M 2.1M 143M 2.13M 14.5M 5.66M 70.58M 5.6M 5.47M 244M
Net income -158M -4.87M -4.28M -3.99M -3.66M -6.88M -467M -6.97M -47.39M -18.51M -231M -18.29M -17.9M -797M -164M -5.08M -4.47M -4.16M -3.82M -7.17M -487M -7.27M -49.44M -19.31M -241M -19.08M -18.67M -832M
Net Debt -382M -11.81M -10.39M -9.67M -8.88M -16.67M -1.13B -16.89M -115M -44.88M -559M -44.35M -43.39M -1.93B -54.59M -1.69M -1.48M -1.38M -1.27M -2.38M -162M -2.41M -16.42M -6.41M -79.95M -6.34M -6.2M -276M
Logo Enimmune corporation
ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
Employees
-
Date Price Change Volume
27/07/26 TWD 16.65 0.00% 21,303
24/07/26 TWD 16.65 0.00% 38,305
23/07/26 TWD 16.65 -0.89% 38,561
22/07/26 TWD 16.80 +3.07% 111,227
21/07/26 TWD 16.30 -1.81% 120,785
  1. Stock Market
  2. Stocks
  3. 6564 Stock